Q2 EPS Estimates for Bone Biologics Lifted by Zacks Research

Bone Biologics Corp. (NASDAQ:BBLG) – Equities researchers at Zacks Research raised their Q2 2026 earnings per share (EPS) estimates for Bone Biologics in a note issued to investors on Friday, May 15th. Zacks Research analyst B. Sorensen now anticipates that the company will earn ($0.39) per share for the quarter, up from their previous estimate of ($0.50). The consensus estimate for Bone Biologics’ current full-year earnings is ($1.93) per share. Zacks Research also issued estimates for Bone Biologics’ Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.52) EPS and FY2027 earnings at ($1.26) EPS.

Separately, Weiss Ratings upgraded Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Bone Biologics currently has an average rating of “Sell”.

Bone Biologics Stock Up 0.9%

BBLG stock opened at $1.26 on Wednesday. Bone Biologics has a twelve month low of $1.05 and a twelve month high of $6.75. The stock’s 50 day moving average is $1.26 and its 200-day moving average is $1.48. The firm has a market capitalization of $2.27 million, a PE ratio of -0.56 and a beta of 0.89.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43).

Hedge Funds Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC increased its stake in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.